Jeffrey C. Baker PhD

Dr. Baker received his doctorate in biochemistry from the University of North Texas and completed post-doctoral studies at the University of California, Berkeley before joining the biosynthetic process development group at Eli Lilly & Co in 1988. While at Lilly, Dr. Baker led the development of several commercial bioproducts from bench top purification to global launch, supported post-launch process development activities, and lead Lilly’s Global Validation Practices Team. After completing his certification as a Lean Six Sigma Black Belt, Dr. Baker led several initiatives related to assessment of control and capability and functional governance processes.

Dr. Baker left Lilly to be Sr. Director of Manufacturing Science and Technology at MedImmune, a subsidiary of AstraZeneca, where he was engaged in organizational redesign and plant start up activities.

Dr. Baker was appointed Deputy Director of the Office of Biotechnology Products in the Center for Drug Evaluation and Research at the United States Food and Drug Administration in 2011.